Intrexon Corp (NYSE:XON)’s share price dropped 6.4% on Tuesday . The stock traded as low as $13.56 and last traded at $13.77. Approximately 2,985,644 shares changed hands during mid-day trading, an increase of 23% from the average daily volume of 2,430,189 shares. The stock had previously closed at $14.71.
XON has been the subject of several analyst reports. Northland Securities reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Intrexon in a report on Friday, October 6th. Bank of America lowered their price target on Intrexon from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, November 10th. Griffin Securities reissued a “buy” rating and set a $55.00 price target on shares of Intrexon in a report on Friday, October 6th. Stifel Nicolaus boosted their price target on Intrexon from $39.00 to $57.00 and gave the stock a “buy” rating in a report on Friday, November 10th. Finally, JMP Securities reissued an “outperform” rating and set a $42.00 price target on shares of Intrexon in a report on Thursday, October 5th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Intrexon currently has an average rating of “Hold” and an average target price of $38.50.
The company has a quick ratio of 1.85, a current ratio of 2.05 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $1,660.00, a price-to-earnings ratio of -12.29 and a beta of 1.33.
Intrexon (NYSE:XON) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. Intrexon had a negative return on equity of 18.68% and a negative net margin of 66.88%. research analysts predict that Intrexon Corp will post -1.06 EPS for the current year.
Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Intrexon by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,433,879 shares of the biotechnology company’s stock worth $106,811,000 after acquiring an additional 147,517 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Intrexon by 5.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 152,576 shares of the biotechnology company’s stock worth $3,675,000 after acquiring an additional 8,148 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Intrexon by 493.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,258 shares of the biotechnology company’s stock worth $271,000 after acquiring an additional 11,854 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in Intrexon during the 2nd quarter worth $593,000. Finally, Trellus Management Company LLC bought a new stake in Intrexon during the 3rd quarter worth $475,000. 77.45% of the stock is owned by institutional investors.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.